Charysse Vandendriessche

Ms. Charysse Vandendriessche


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2024 in eClinicalMedicine
Verified
Journal Article
Open access
ABArnout Bruggeman
Arnout Bruggeman
CVCharysse Vandendriessche
Charysse Vandendriessche
HHHannelore Hamerlinck
Hannelore Hamerlinck
DLDanny De Looze
Danny De Looze
DTDavid J. Tate
David J. Tate
PSPatrick Santens
Patrick Santens
Dysregulation of the gut microbiome has been implicated in Parkinson's disease (PD). This study aimed to evaluate the clinical effects and safety of a single faecal microbiota transplantation (FMT) in patients with early-stage PD. The GUT-PARFECT trial, a single-centre randomised, double-blind, placebo-controlled trial was conducted at Ghent University Hospital between December 01, 2020 and December 12, 2022. Participants (aged 50–65 years, Hoehn and Yahr stage 2) were randomly assigned to receive nasojejunal FMT with either healthy donor stool or their own stool. Computer-generated randomisation was done in a 1:1 ratio through permutated-block scheduling. Treatment allocation was concealed for participants and investigators. The primary outcome measure at 12 months was the change in the Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) motor score obtained during off-medication evaluations. Intention-to-treat analysis was performed using a mixed model for repeated measures analysis. This completed trial is registered on ClinicalTrials.gov (NCT03808389). Between December 2020 and December 2021, FMT procedures were conducted on 46 patients with PD: 22 in the healthy donor group and 24 in the placebo group. Clinical evaluations were performed at baseline, 3, 6, and 12 months post-FMT. Full data analysis was possible for 21 participants in the healthy donor group and 22 in the placebo group. After 12 months, the MDS-UPDRS motor score significantly improved by a mean of 5.8 points (95% CI −11.4 to −0.2) in the healthy donor group and by 2.7 points (−8.3 to 2.9) in the placebo group (p = 0.0235). Adverse events were limited to temporary abdominal discomfort. Our findings suggested a single FMT induced mild, but long-lasting beneficial effects on motor symptoms in patients with early-stage PD. These findings highlight the potential of modulating the gut microbiome as a therapeutic approach and warrant a further exploration of FMT in larger cohorts of patients with PD in various disease stages. Flemish PD patient organizations (VPL and Parkili), 10.13039/501100003130 Research Foundation Flanders (FWO), 10.13039/100019486 Biocodex Microbiota Foundation .

10 July 2023 in The EMBO Journal
Verified
Journal Article
Open access
JXJunhua Xie
Junhua Xie
ABArnout Bruggeman
Arnout Bruggeman
CNClint De Nolf
Clint De Nolf
CVCharysse Vandendriessche
Charysse Vandendriessche
GIGriet Van Imschoot
Griet Van Imschoot
Roosmarijn VandenbrouckeRoosmarijn Vandenbroucke
Roosmarijn Vandenbroucke
Accumulating evidence indicates that gut microbiota dysbiosis is associated with increased blood–brain barrier (BBB) permeability and contributes to Alzheimer's disease (AD) pathogenesis. In contrast, the influence of gut microbiota on the blood‐cerebrospinal fluid (CSF) barrier has not yet been studied. Here, we report that mice lacking gut microbiota display increased blood‐CSF barrier permeability associated with disorganized tight junctions (TJs), which can be rescued by recolonization with gut microbiota or supplementation with short‐chain fatty acids (SCFAs). Our data reveal that gut microbiota is important not only for the establishment but also for the maintenance of a tight barrier. Also, we report that the vagus nerve plays an important role in this process and that SCFAs can independently tighten the barrier. Administration of SCFAs in App NL‐G‐F mice improved the subcellular localization of TJs at the blood‐CSF barrier, reduced the β‐amyloid (Aβ) burden, and affected microglial phenotype. Altogether, our results suggest that modulating the microbiota and administering SCFAs might have therapeutic potential in AD via blood‐CSF barrier tightening and maintaining microglial activity and Aβ clearance.

22 February 2018 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
SSSophie Steeland
Sophie Steeland
NGNina Gorlé
Nina Gorlé
CVCharysse Vandendriessche
Charysse Vandendriessche
SBSriram Balusu
Sriram Balusu
MBMarjana Brkic
Marjana Brkic
Roosmarijn VandenbrouckeRoosmarijn Vandenbroucke
Roosmarijn Vandenbroucke
Alzheimer's disease (AD) is the most common form of dementia, and neuroinflammation is an important hallmark of the pathogenesis. Tumor necrosis factor (TNF) might be detrimental in AD, though the results coming from clinical trials on anti‐TNF inhibitors are inconclusive. TNFR1, one of the TNF signaling receptors, contributes to the pathogenesis of AD by mediating neuronal cell death. The blood–cerebrospinal fluid (CSF) barrier consists of a monolayer of choroid plexus epithelial (CPE) cells, and AD is associated with changes in CPE cell morphology. Here, we report that TNF is the main inflammatory upstream mediator in choroid plexus tissue in AD patients. This was confirmed in two murine AD models: transgenic APP/PS1 mice and intracerebroventricular (icv) AβO injection. TNFR1 contributes to the morphological damage of CPE cells in AD, and TNFR1 abrogation reduces brain inflammation and prevents blood–CSF barrier impairment. In APP/PS1 transgenic mice, TNFR1 deficiency ameliorated amyloidosis. Ultimately, genetic and pharmacological blockage of TNFR1 rescued from the induced cognitive impairments. Our data indicate that TNFR1 is a promising therapeutic target for AD treatment.

30 May 2016 in Mammalian Genome
Verified
Journal Article
Closed access
PDF file
CCCaroline Van Cauwenberghe
Caroline Van Cauwenberghe
CVCharysse Vandendriessche
Charysse Vandendriessche
CLClaude Libert
Claude Libert
Roosmarijn VandenbrouckeRoosmarijn Vandenbroucke
Roosmarijn Vandenbroucke

15 November 2020 in Cells
Verified
Journal Article
Open access
PDF file
CVCharysse Vandendriessche
Charysse Vandendriessche
ABArnout Bruggeman
Arnout Bruggeman
CCCaroline Van Cauwenberghe
Caroline Van Cauwenberghe
Roosmarijn VandenbrouckeRoosmarijn Vandenbroucke
Roosmarijn Vandenbroucke
Alzheimer’s disease (AD) and Parkinson’s disease (PD) are incurable, devastating neurodegenerative disorders characterized by the formation and spreading of protein aggregates throughout the brain. Although the exact spreading mechanism is not completely understood, extracellular vesicles (EVs) have been proposed as potential contributors. Indeed, EVs have emerged as potential carriers of disease-associated proteins and are therefore thought to play an important role in disease progression, although some beneficial functions have also been attributed to them. EVs can be isolated from a variety of sources, including biofluids, and the analysis of their content can provide a snapshot of ongoing pathological changes in the brain. This underlines their potential as biomarker candidates which is of specific relevance in AD and PD where symptoms only arise after considerable and irreversible neuronal damage has already occurred. In this review, we discuss the known beneficial and detrimental functions of EVs in AD and PD and we highlight their promising potential to be used as biomarkers in both diseases.

15 July 2019 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
TLTjasa Lepko
Tjasa Lepko
MPMelanie Pusch
Melanie Pusch
TMTamara Müller
Tamara Müller
DSDorothea Schulte
Dorothea Schulte
JEJanina Ehses
Janina Ehses
JNJovica Ninkovic
Jovica Ninkovic
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.